SVB Leerink Cuts Bluebird Bio (NASDAQ:BLUE) Price Target to $8.00
SVB Leerink Cuts Bluebird Bio (NASDAQ:BLUE) Price Target to $8.00
bluebird bio (NASDAQ:BLUE – Get Rating) had its target price trimmed by SVB Leerink from $9.00 to $8.00 in a report published on Monday morning, Benzinga reports. The brokerage currently has a market perform rating on the biotechnology company's stock. SVB Leerink also issued estimates for bluebird bio's Q4 2022 earnings at ($1.18) EPS, FY2022 earnings at ($5.13) EPS, Q1 2023 earnings at ($0.64) EPS, Q2 2023 earnings at ($0.62) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.48) EPS, FY2023 earnings at ($2.31) EPS and FY2024 earnings at ($1.59) EPS.
据Benzinga报道，在周一上午发布的一份报告中，SVB Leerink将蓝鸟生物(纳斯达克：Blue-Get Rating)的目标价从9.00美元下调至8.00美元。该经纪公司目前对这家生物技术公司的股票进行了市场表现评级。SVB Leerink还发布了对蓝鸟生物2022财年第四季度每股收益(1.18美元)、2022财年每股收益(5.13美元)、2023年第一季度每股收益(0.64美元)、2023年第二季度每股收益(0.62美元)、2023年第三季度每股收益(0.58美元)、2023年第四季度每股收益(0.48美元)、2023财年每股收益(2.31美元)和2024财年每股收益(1.59美元)的预期。
Other equities analysts have also issued reports about the stock. StockNews.com assumed coverage on shares of bluebird bio in a research report on Wednesday, October 12th. They issued a sell rating on the stock. Royal Bank of Canada dropped their price objective on shares of bluebird bio to $8.00 and set a sector perform rating on the stock in a research report on Tuesday, November 8th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, bluebird bio currently has a consensus rating of Hold and an average target price of $6.75.
其他股票分析师也发布了有关该股的报告。斯托克新闻网在10月12日星期三的一份研究报告中对蓝鸟生物的股票进行了报道。他们对这只股票发布了卖出评级。11月8日，加拿大皇家银行在一份周二的研究报告中将蓝鸟生物的股价目标下调至8.00美元，并对该股设定了行业表现评级。三位分析师对该股的评级为卖出，六位分析师给出了持有评级，一位分析师给出了该公司的买入评级。根据MarketBeat的数据，蓝鸟生物目前的共识评级为持有，平均目标价为6.75美元。
bluebird bio Trading Down 3.1 %
蓝鸟生物交易下跌3.1%
NASDAQ BLUE opened at $6.33 on Monday. The firm has a market capitalization of $524.90 million, a P/E ratio of -1.04 and a beta of 0.99. The firm's fifty day moving average price is $7.38 and its two-hundred day moving average price is $6.52. bluebird bio has a 1 year low of $2.87 and a 1 year high of $8.58.
纳斯达克蓝周一开盘报6.33美元。该公司的市值为5.249亿美元，市盈率为-1.04，贝塔系数为0.99。该公司的50日移动均线价格为7.38美元，200日移动均线价格为6.52美元。蓝鸟生物的一年低点为2.87美元，一年高位为8.58美元。
Insider Activity at bluebird bio
蓝鸟生物的内幕活动
In other bluebird bio news, Director Nick Leschly sold 4,290 shares of the stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $7.80, for a total transaction of $33,462.00. Following the sale, the director now directly owns 280,149 shares in the company, valued at $2,185,162.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 9,506 shares of company stock worth $72,088. Corporate insiders own 2.20% of the company's stock.
在其他蓝鸟传记方面，董事尼克·莱施利在1月11日星期三的交易中出售了4,290股蓝鸟股票。这些股票以7.80美元的平均价格出售，总成交额为33,462.00美元。交易完成后，董事现在直接持有该公司280,149股股份，价值2185,162.20美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在这个环节。在过去的三个月里，内部人士已经出售了9506股公司股票，价值72,088美元。企业内部人士持有该公司2.20%的股份。
Institutional Investors Weigh In On bluebird bio
机构投资者参与蓝鸟生物
Large investors have recently bought and sold shares of the company. Caxton Associates LP grew its stake in bluebird bio by 559.6% during the second quarter. Caxton Associates LP now owns 220,154 shares of the biotechnology company's stock worth $911,000 after buying an additional 186,778 shares in the last quarter. Virtu Financial LLC bought a new position in shares of bluebird bio in the second quarter worth about $291,000. Monaco Asset Management SAM bought a new position in shares of bluebird bio in the second quarter worth about $1,267,000. WINTON GROUP Ltd bought a new position in shares of bluebird bio in the second quarter worth about $128,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of bluebird bio by 374.8% in the third quarter. Cubist Systematic Strategies LLC now owns 453,763 shares of the biotechnology company's stock worth $2,872,000 after acquiring an additional 358,196 shares during the last quarter. 79.01% of the stock is currently owned by institutional investors and hedge funds.
大型投资者最近买卖了该公司的股票。第二季度，Caxton Associates LP对蓝鸟生物的持股增加了559.6%。Caxton Associates LP现在拥有220,154股这家生物技术公司的股票，价值911,000美元，上个季度又购买了186,778股。Virtu Financial LLC在第二季度购买了蓝鸟生物的新头寸，价值约29.1万美元。摩纳哥资产管理公司SAM在第二季度购买了蓝鸟生物的新头寸，价值约1,267,000美元。Winton Group Ltd在第二季度购买了蓝鸟生物的新头寸，价值约12.8万美元。最后，立体主义系统战略有限责任公司在第三季度增持了374.8%的蓝鸟生物股票。Cubist Systems Strategy LLC在上个季度增持了358,196股后，现在拥有这家生物技术公司453,763股股票，价值2,872,000美元。79.01%的股票目前由机构投资者和对冲基金持有。
About bluebird bio
关于蓝鸟传记
(Get Rating)
(获取评级)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
蓝鸟生物公司是一家生物技术公司，研究、开发和商业化针对严重遗传病的变革性基因疗法。其用于治疗严重遗传性疾病的候选产品包括用于治疗输血依赖型β-地中海贫血的贝替贝吉基因Autotemcel；用于治疗镰状细胞病(SCD)的lovotieglogene autemcel；以及用于治疗大脑肾上腺脑白质营养不良的伊利伐多烯Autotemcel。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- 免费获取StockNews.com关于蓝鸟生物的研究报告(蓝色)
- AMD仍是市面上最好的半导体股票之一
- 两大股利大王：强生还是雅培？
- 网络安全类股已经见底了吗？
- 联合太平洋，诺福克南方进入购买区
- 柔顺治疗公司的差距增加了34%：未来还会有更多的好处吗？
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
获得蓝鸟生物日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对蓝鸟生物和相关公司的最新新闻和分析师评级的每日简明摘要。
译文内容由第三方软件翻译。